The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies
The approval is supported by data from three pivotal clinical trials
Elanco expects Befrena to launch in the US in the first half of 2026
Coverage has been significantly strengthened across key therapeutic categories, including anti-tubercular, anti-diabetic and anti-cancer medicines, as well as iron supplements, thereby ensuring more comprehensive standardisation of medicines used under various National Health Programmes
The new facility is expected to generate 500-600 new jobs in the region
The study found BIC/LEN to be statistically non-inferior to BIKTARVY, Gilead’s current standard-of-care therapy
The expansion includes a larger technical and service team and increased local procurement
The new powder formulation gives children and adults living with Rett syndrome greater flexibility and choice in dose volume and taste
The approval of Augmentin XR, granted to USAntibiotics, directly supports the CNPV program’s goals
At the trial’s pre-specified interim analysis, giredestrant achieved a hazard ratio of 0.70, marking a statistically significant improvement in invasive disease-free survival
Subscribe To Our Newsletter & Stay Updated
